OBJECTIVE: To explore the cost-effectiveness of parenteral artesunate for the treatment of severe malaria in children and its potential impact on hospital budgets. METHODS: The costs of inpatient care of children with severe malaria were assessed in four of the 11 sites included in the African Quinine Artesunate Malaria Treatment trial, conducted with over 5400 children. The drugs, laboratory tests and intravenous fluids provided to 2300 patients from admission to discharge were recorded, as was the length of inpatient stay, to calculate the cost of inpatient care. The data were matched with pooled clinical outcomes and entered into a decision model to calculate the cost per disability-adjusted life year (DALY) averted and the cost per death averted. FINDINGS: The mean cost of treating severe malaria patients was similar in the two study groups: 63.5 United States dollars (US$) (95% confidence interval, CI: 61.7-65.2) in the quinine arm and US$ 66.5 (95% CI: 63.7-69.2) in the artesunate arm. Children treated with artesunate had 22.5% lower mortality than those treated with quinine and the same rate of neurological sequelae: (artesunate arm: 2.3 DALYs per patient; quinine arm: 3.0 DALYs per patient). Compared with quinine as a baseline, artesunate showed an incremental cost per DALY averted and an incremental cost per death averted of US$ 3.8 and US$ 123, respectively. CONCLUSION: Artesunate is a highly cost-effective and affordable alternative to quinine for treating children with severe malaria. The budgetary implications of adopting artesunate for routine use in hospital-based care are negligible.
OBJECTIVE: To explore the cost-effectiveness of parenteral artesunate for the treatment of severe malaria in children and its potential impact on hospital budgets. METHODS: The costs of inpatient care of children with severe malaria were assessed in four of the 11 sites included in the African QuinineArtesunateMalaria Treatment trial, conducted with over 5400 children. The drugs, laboratory tests and intravenous fluids provided to 2300 patients from admission to discharge were recorded, as was the length of inpatient stay, to calculate the cost of inpatient care. The data were matched with pooled clinical outcomes and entered into a decision model to calculate the cost per disability-adjusted life year (DALY) averted and the cost per death averted. FINDINGS: The mean cost of treating severe malariapatients was similar in the two study groups: 63.5 United States dollars (US$) (95% confidence interval, CI: 61.7-65.2) in the quinine arm and US$ 66.5 (95% CI: 63.7-69.2) in the artesunate arm. Children treated with artesunate had 22.5% lower mortality than those treated with quinine and the same rate of neurological sequelae: (artesunate arm: 2.3 DALYs per patient; quinine arm: 3.0 DALYs per patient). Compared with quinine as a baseline, artesunate showed an incremental cost per DALY averted and an incremental cost per death averted of US$ 3.8 and US$ 123, respectively. CONCLUSION:Artesunate is a highly cost-effective and affordable alternative to quinine for treating children with severe malaria. The budgetary implications of adopting artesunate for routine use in hospital-based care are negligible.
Authors: Y Lubell; S Yeung; A M Dondorp; N P Day; F Nosten; E Tjitra; Md Abul Faiz; E Bin Yunus; N M Anstey; S K Mishra; S Mohanty; N J White; A J Mills Journal: Trop Med Int Health Date: 2009-01-28 Impact factor: 2.622
Authors: Behzad Nadjm; Ben Amos; George Mtove; Jan Ostermann; Semkini Chonya; Hannah Wangai; Juma Kimera; Walii Msuya; Frank Mtei; Denise Dekker; Rajabu Malahiyo; Raimos Olomi; John A Crump; Christopher J M Whitty; Hugh Reyburn Journal: BMJ Date: 2010-03-30
Authors: Arjen M Dondorp; Caterina I Fanello; Ilse C E Hendriksen; Ermelinda Gomes; Amir Seni; Kajal D Chhaganlal; Kalifa Bojang; Rasaq Olaosebikan; Nkechinyere Anunobi; Kathryn Maitland; Esther Kivaya; Tsiri Agbenyega; Samuel Blay Nguah; Jennifer Evans; Samwel Gesase; Catherine Kahabuka; George Mtove; Behzad Nadjm; Jacqueline Deen; Juliet Mwanga-Amumpaire; Margaret Nansumba; Corine Karema; Noella Umulisa; Aline Uwimana; Olugbenga A Mokuolu; Olanrewaju T Adedoyin; Wahab B R Johnson; Antoinette K Tshefu; Marie A Onyamboko; Tharisara Sakulthaew; Wirichada Pan Ngum; Kamolrat Silamut; Kasia Stepniewska; Charles J Woodrow; Delia Bethell; Bridget Wills; Martina Oneko; Tim E Peto; Lorenz von Seidlein; Nicholas P J Day; Nicholas J White Journal: Lancet Date: 2010-11-07 Impact factor: 79.321
Authors: Wirichada Pongtavornpinyo; Shunmay Yeung; Ian M Hastings; Arjen M Dondorp; Nicholas P J Day; Nicholas J White Journal: Malar J Date: 2008-11-02 Impact factor: 2.979
Authors: Arjen M Dondorp; Richard J Maude; Ilse C E Hendriksen; Nicholas P Day; Nicholas J White Journal: J Infect Dis Date: 2012-06-25 Impact factor: 5.226
Authors: James G Kahn; Nicholas Muraguri; Brian Harris; Eric Lugada; Thomas Clasen; Mark Grabowsky; Jonathan Mermin; Shahnaaz Shariff Journal: PLoS One Date: 2012-02-08 Impact factor: 3.240
Authors: Giovanfrancesco Ferrari; Henry M Ntuku; Christian Burri; Antoinette K Tshefu; Stephan Duparc; Pierre Hugo; Didier K Mitembo; Amanda Ross; Philippe L Ngwala; Joseph N Luwawu; Papa N Musafiri; Symphorien E Ngoie; Christian Lengeler Journal: Malar J Date: 2015-05-30 Impact factor: 2.979
Authors: Kafula Silumbe; Joshua O Yukich; Busiku Hamainza; Adam Bennett; Duncan Earle; Mulakwa Kamuliwo; Richard W Steketee; Thomas P Eisele; John M Miller Journal: Malar J Date: 2015-05-20 Impact factor: 2.979
Authors: Rebecca L Brander; Marcia R Weaver; Patricia B Pavlinac; Grace C John-Stewart; Stephen E Hawes; Judd L Walson Journal: Clin Infect Dis Date: 2020-01-06 Impact factor: 9.079